SCHEMBL8662572

SCHEMBL8662572

c1ccc2c(c1)Cc1cc3ccccc3cc1C2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
CYP3A4 P08684 2/20 0.48
TSHR P16473 2/20 0.48
HSD17B10 Q99714 2/20 0.47
KDM4E B2RXH2 1/20 0.47
NPC1 O15118 1/20 0.47
TP53 P04637 1/20 0.47
CYP2D6 P10635 1/20 0.47
MAPT P10636 1/20 0.47
CYP2C9 P11712 1/20 0.47
PKM P14618 1/20 0.47
MAPK1 P28482 1/20 0.47
CYP2C19 P33261 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CYP1A2 P05177 1/20 0.46
DRD1 P21728 5/20 0.42
DRD5 P21918 5/20 0.42
DRD2 P14416 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30376019 1.00 MEN1 (0.48) MEN1KMT2ACYP3A4TSHRHSD17B10
SCHEMBL14800367 0.95 MEN1 (0.44) MEN1KMT2ACYP3A4TSHRHSD17B10
SCHEMBL1808685 0.94 MEN1 (0.52) MEN1KMT2ACYP3A4TSHRHSD17B10
SCHEMBL7914941 0.94 MEN1 (0.52) MEN1KMT2ACYP3A4TSHRHSD17B10
SCHEMBL31274423 0.94 MEN1 (0.52) MEN1KMT2ACYP3A4TSHRHSD17B10
SCHEMBL29604701 0.94 MEN1 (0.52) MEN1KMT2ACYP3A4TSHRHSD17B10
Anthracene SCHEMBL2876495 0.91 CYP3A4 (0.50) MEN1KMT2ACYP3A4TSHRHSD17B10
SCHEMBL19810032 0.88 MEN1 (0.48) MEN1KMT2ACYP3A4TSHRHSD17B10
SCHEMBL19810040 0.88 CYP1A2 (0.46) MEN1KMT2ACYP3A4TSHRHSD17B10
SCHEMBL4621881 0.85 MEN1 (0.41) MEN1KMT2ACYP3A4TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110662737-B Method for producing methyl methacrylate or methacrylic acid 三菱化学英国有限公司 2023-04-28 CN claimed
US-11174215-B2 Method of producing methyl methacrylate or methacrylic acid Mitsubishi Chemical UK Limited (GB) 2021-11-16 US claimed
US-10693074-B2 5,12-dihydrotetracene derivative and organic electroluminescence device using the same LUMINESCENCE TECHNOLOGY CORP. (TW) 2020-06-23 US claimed
EP-3601214-A1 METHOD OF PRODUCING METHYL METHACRYLATE OR METHACRYLIC ACID Lucite International UK Limited (GB) 2020-02-05 EP claimed
US-20200031754-A1 METHOD OF PRODUCING METHYL METHACRYLATE OR METHACRYLIC ACID Mitsubishi Chemical UK Limited (GB) 2020-01-30 US claimed
CN-110662737-A Method for producing methyl methacrylate or methacrylic acid 卢塞特英国国际有限公司 2020-01-07 CN claimed
US-20190229270-A1 5,12-DIHYDROTETRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME LUMINESCENCE TECHNOLOGY CORPORATION (TW) 2019-07-25 US claimed
WO-2018172783-A1 METHOD OF PRODUCING METHYL METHACRYLATE OR METHACRYLIC ACID LUCITE INTERNATIONAL UK LIMITED (GB) 2018-09-27 WO claimed
CN-110662737-B Method for producing methyl methacrylate or methacrylic acid 三菱化学英国有限公司 2023-04-28 CN disclosed
US-11174215-B2 Method of producing methyl methacrylate or methacrylic acid Mitsubishi Chemical UK Limited (GB) 2021-11-16 US disclosed
US-11005047-B2 Heteroaromatic compound and organic electroluminescence device using the same LUMINESCENCE TECHNOLOGY CORP. (TW) 2021-05-11 US disclosed
US-10844043-B2 Heteroaromatic compound and organic electroluminescence device using the same LUMINESCENCE TECHNOLOGY CORP. (TW) 2020-11-24 US disclosed
US-10693074-B2 5,12-dihydrotetracene derivative and organic electroluminescence device using the same LUMINESCENCE TECHNOLOGY CORP. (TW) 2020-06-23 US disclosed
US-10693074-B2 5,12-dihydrotetracene derivative and organic electroluminescence device using the same LUMINESCENCE TECHNOLOGY CORP. (TW) 2020-06-23 US disclosed
CN-102869660-A Aminothiazolones as estrogen related receptor-alpha modulators JANSSEN PHARMACEUTICA NV 2013-01-09 CN disclosed
US-5808154-A Process for the production of an aromatic hydrazo compound TOYO INK MANUFACTURING CO., LTD. (JP) 1998-09-15 US disclosed
EP-0391606-B1 Process for the production of an aromatic hydrazo compound TOYO INK MFG CO (JP) 1995-07-05 EP disclosed
US-4981962-A CHARGE TRANSFER COMPLEXES CIBA-GEIGY CORPORATION (US) 1991-01-01 US disclosed
EP-0391606-A1 Process for the production of an aromatic hydrazo compound TOYO INK MANUFACTURING CO., LTD. (JP) 1990-10-10 EP disclosed
US-4617151-A 2- or 2,3-substituted 5,6,11,12-tetrathiotetracene and 5,6,11,12-tetraselenotetracene CIBA-GEIGY CORPORATION (US) 1986-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10844043-B2 Heteroaromatic compound and organic electroluminescence device using the same VDAC1, TRPC6, TRPC5 MEN1 1722/4885KMT2A 1998/4885CYP3A4 30/4885
US-11174215-B2 Method of producing methyl methacrylate or methacrylic acid MMAB, MEP1A, MTR MEN1 683/4885KMT2A 461/4885CYP3A4 1303/4885
US-11005047-B2 Heteroaromatic compound and organic electroluminescence device using the same ARNT, TRPC6, DDT MEN1 2365/4885KMT2A 1721/4885CYP3A4 23/4885
US-10693074-B2 5,12-dihydrotetracene derivative and organic electroluminescence device using the same MT-ND5, DLD, TRPC5 MEN1 4202/4885KMT2A 1792/4885CYP3A4 551/4885
US-20200031754-A1 METHOD OF PRODUCING METHYL METHACRYLATE OR METHACRYLIC ACID MMAB, MEP1A, MTR MEN1 683/4885KMT2A 461/4885CYP3A4 1303/4885
US-20190229270-A1 5,12-DIHYDROTETRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME MT-ND5, DLD, TRPC5 MEN1 4202/4885KMT2A 1792/4885CYP3A4 551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.